TY - JOUR
T1 - Hijacking CRISPR-Cas for high-throughput bacterial metabolic engineering: advances and prospects
AU - Mougiakos, Ioannis
AU - Bosma, Elleke F.
AU - Ganguly , Joyshree
AU - van der Oost, John
AU - van Kranenburg, Richard
N1 - c 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creative-commons.org/licenses/by-nc-nd/4.0/).
PY - 2018
Y1 - 2018
N2 - High engineering efficiencies are required for industrial strain development. Due to its user-friendliness and its stringency, CRISPR-Cas-based technologies have strongly increased genome engineering efficiencies in bacteria. This has enabled more rapid metabolic engineering of both the model host Escherichia coli and non-model organisms like Clostridia, Bacilli, Streptomycetes and cyanobacteria, opening new possibilities to use these organisms as improved cell factories. The discovery of novel Cas9-like systems from diverse microbial environments will extend the repertoire of applications and broaden the range of organisms in which it can be used to create novel production hosts. This review analyses the current status of prokaryotic metabolic engineering towards the production of biotechnologically relevant products, based on the exploitation of different CRISPR-related DNA/RNA endonuclease variants.
AB - High engineering efficiencies are required for industrial strain development. Due to its user-friendliness and its stringency, CRISPR-Cas-based technologies have strongly increased genome engineering efficiencies in bacteria. This has enabled more rapid metabolic engineering of both the model host Escherichia coli and non-model organisms like Clostridia, Bacilli, Streptomycetes and cyanobacteria, opening new possibilities to use these organisms as improved cell factories. The discovery of novel Cas9-like systems from diverse microbial environments will extend the repertoire of applications and broaden the range of organisms in which it can be used to create novel production hosts. This review analyses the current status of prokaryotic metabolic engineering towards the production of biotechnologically relevant products, based on the exploitation of different CRISPR-related DNA/RNA endonuclease variants.
U2 - 10.1016/j.copbio.2018.01.002
DO - 10.1016/j.copbio.2018.01.002
M3 - Journal article
C2 - 29414054
SN - 0958-1669
VL - 50
SP - 146
EP - 157
JO - Current Opinion in Biotechnology
JF - Current Opinion in Biotechnology
ER -